Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women

Journal of Bone and Mineral Research

Volumn 15, Issue 3, 2000, Pages 594-598

  Eastell, R ^a,f   Mallinak, N ^b   Weiss, S ^c   Ettinger, M ^d   Pettinger, M ^b   Cain, D ^b   Flessland, K ^b   Chesnut III, C ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Ostex International Inc   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Clin Res Center of South Florida   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; PEPTIDE HORMONE;

ADULT; AGED; ARTICLE; CALCULATION; DATA ANALYSIS; DIETARY INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIFESTYLE; OSTEOLYSIS; PATIENT MONITORING; POSTMENOPAUSE; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; TREATMENT PLANNING;

EID: 0034102078     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.3.594     Document Type: Article

References (22)

1. Chesnut C, Bell N, Clark G, Drinkwater B, English S, Johnston C, Notelovitz M, Rosen C, Cain D, Flessland K, Mallinak N 1997 Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29-37.
2. Garnero P, Shi W, Gineyts E, Karpt D, Delmas P 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
3. Liberman U, Weiss S, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
4. Delmas P, Bjarnason N, Mitlak B, Ravoux A, Shah A, Huster W, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
5. Calvo M, Eyre D, Gundberg C 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333-338.
6. Hanson D, Weis M, Bollen A, Maslan S, Singer F, Eyre D 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258.
7. Hanson D, Eyre D 1996 Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 271:26508-26516.
8. Bonde M, Qvist P, Fledelius C, Riss B, Christiansen C 1995 Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps®): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868.
9. Robins S, Woitge H, Hesley R, Ju J, Seyedin S, Seibel M 1994 Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649.
10. Machado A, Hannon R, Eastell R 1999 Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14:602-608.
11. Clemens JD, Herrick M, Singer F, Eyre D 1997 Evidence that serum NTX (collagen type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43: 2058-2063.
12. Mallinak N, Pettinger, Cain D, Flessland K 1998 Serum NTX levels monitor hormone replacement therapy in early postmenopausal women. J Bone Miner Res 23(Suppl 5):F434.
13. Gertz G, Clemens JD, Holland S, Yuan W, Greenspan S 1998 Application of a new serum assay for type I collagen crosslinked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 63:102-106.
14. Scariano, J, Vanderjagt D, Thacher T, Isichei C, Hollis B, Glew R 1998 Calcium supplements increase the serum levels of crosslinked N-telopeptides of bone collagen and parathyroid hormone in rachitic Nigerian children. Clin Biochem 31:421-427.
15. Prestwood K, Thompson D, Kenny A, Seibel M, Pilbeam C, Raisz L 1999 Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 84:179-183.
16. Woitge H, Pecherstorfer M, Li Y, Keck A-V, Horn E, Zeigler R, Seibel M 1999 Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792-801.
17. Willet WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witchi J, Hennekins CH, Speizer, FE. 1985 Reproducibility and validity of a semi-quantitative food frequency questionnaire. Am J Epidemiol 122:51-65.
18. Gertz B, Shao P, Hanson D, Quan H, Harris S, Genant H, Chesnut C, Eyre D 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142.
19. Fraser C 1992 Biological variation in clinical chemistry. An update: Collated data, 1988-1991. Arch Pathol Lab Med 116:916-923.
20. Greenspan S, Parker R, Ferguson L, Rosen H, Maitland-Ramsey L, Karpf D 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13:1431-1438.
21. Greenspan S, Morgan J, Furstoss K, Rafferty J, Carpenter R, Pettinger M, Clemens J 1998 Measuring response to alendronate therapy in elderly women by serum cross-linked N-telopeptides (NTX) immunoassay. J Bone Miner Res 23(Suppl 5):SA431.
22. Hannon RA, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13:1124-1133.